Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience

Upfront docetaxel or novel hormonal agents (NHA) such as abiraterone and enzalutamide have become the standard of care for metastatic hormone sensitive prostate cancer (mHSPC). We evaluated real-world management of patients treated with these agents at a single center. We identified 94 de novo mHSPC...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2022-08, Vol.17 (8), p.e0264800-e0264800
Main Authors: Guin, Sunny, Liaw, Bobby K, Jun, Tomi, Ayers, Kristin, Patel, Bonny, O'Connell, Timmy, Deitz, Matthew, Klein, Michael, Mullaney, Tommy, Prentice, Tony, Newman, Scott, Fink, Marc, Zhou, Xiang, Schadt, Eric E, Chen, Rong, Oh, William K
Format: Article
Language:English
Subjects:
Automation
Biology and Life Sciences
Cancer therapies
Clinical trials
Complications and side effects
Data warehouses
Diagnosis
Evaluation
Hazard assessment
Hospitals
Information retrieval
Medical diagnosis
Medicine and Health Sciences
Metastases
Metastasis
Patients
Prostate cancer
Statistical analysis
Statistical models
Survival
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Upfront docetaxel or novel hormonal agents (NHA) such as abiraterone and enzalutamide have become the standard of care for metastatic hormone sensitive prostate cancer (mHSPC). We evaluated real-world management of patients treated with these agents at a single center. We identified 94 de novo mHSPC patients; 52 and 42 treated with upfront docetaxel and NHAs, respectively. NHAs were associated with a median TTNT of 20.7 months compared to 10.1 months with docetaxel (log-rank p = 0.023). We also observed median PSA PFS of 19 months for NHAs and 13.2 months for docetaxel (p = 0.069). However, OS between the two treatment groups was unchanged. Among docetaxel treated patients, TTNT was shorter among those with high metastasis burden (9.63 vs 25.5 months, p = 0.026) which was not observed among NHA treated patients (25.1 vs 20.7 months, p = 0.79). Regardless of treatment, lower post-treatment PSA levels were associated with improved TTNT (58.95 vs. 11.57 vs. 9.4 months for PSA [less than or equal to]0.2, 0.2-0.4, >0.4ng/ml, respectively; p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0264800